It was spurred by the Intercept’s disclosure of Musk’s hitherto-secret White House email address: [email protected]. When the Intercept first published Musk’s email address, on March 6, journalist ...

We expect disappointing results in the first quarter will be balanced by higher-than-anticipated growth in the second half.

Investors are worried Novo Nordisk's competition with Eli Lilly is heating up and that the first-to-market GLP-1 leader is ...

A man is suing the manufacturers of Ozempic, alleging the diabetes drug caused him to go blind. The medication, containing semaglutide, works by regulating blood sugar and suppressing hunger. While ...

As we learn more about GLP-1 drugs like Wegovy and Zepbound, early research suggests that they may be able to improve COPD ...

The maker of Ozempic and Wegovy expects lower sales and profit growth this year despite recent victories against compounders.

Here is what can happen to the body once you finish a course of Ozempic as a simulation reveals what the diabetes drug does ...

Wegovy and Ozempic are both semaglutide weight loss medications, but they’re prescribed differently based on who qualifies.

Novo Nordisk is collaborating with multiple telehealth organizations in an effort to increase patient access to authentic ...

Novo Nordisk A/S' Q1 earnings reveal strong growth in semaglutide-driven sales despite a slight revenue miss. Learn more ...

Novo Nordisk's Q1 results show a dramatic expansion in sales beyond the US. Nevertheless, issues remain, and its outlook for ...